VA South Texas Health Care System, San Antonio
Welcome,         Profile    Billing    Logout  
 3 Trials 
2 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cusi, Kenneth
NCT03459079: Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease

Hourglass Jan 2021 - Dec 2021 : Safety and efficacy data
Hourglass Apr 2019 - Dec 2019 : Completion of enrollment in P2 trial in type 2 diabetes patients with NAFLD
Checkmark Trial initiation
Sep 2018 - Sep 2018: Trial initiation
Completed
2
128
US
Lanifibranor, IVA 337, Placebo
University of Florida, Inventiva Pharma
Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM)
04/23
06/23
NCT02815891: A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

Recruiting
N/A
15000
Europe, US
Target PharmaSolutions, Inc.
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
07/36
07/36
Mortensen, Eric M
No trials found
Restrepo, Marcos I
No trials found
Cunningham, Sue A
No trials found

Download Options